120 West 45th Street
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services to accelerate and increase the efficiency of drug discovery for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and was a co-founder of leading biotech companies including Nimbus Therapeutics, Morphic Therapeutic, and others. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science.
A great company is made up of great people, and Schrödinger is no exception. Whether you’re in Administration, Sales, Finance, Law, Engineering, IT, or Science, we are always on the lookout for exceptional candidates who can join us and make our team stronger. You will find Schrödinger to be a dynamic, energetic, and fast-paced place to work, where you get to interact with some of the smartest and hardest working people you’ll ever meet. If you’ve ever had a curiosity about science, and how science can improve people’s lives, then there’s no
better place to be than Schrödinger.
Stock Exchange: NASDAQ
Stock Symbol: SDGR
72 articles with Schrödinger
Schrödinger Announces Expansion of Multi-Target Research Collaboration with Takeda and Achievement of First Significant Preclinical Milestone in Lead Program
Schrödinger announced the expansion of its multi-year, multi-target drug discovery collaboration with Takeda, as well as Schrödinger’s achievement of the first significant preclinical milestone for the collaboration’s most advanced program.
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
Schrödinger announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.
Schrödinger and Qu & Co Announce Collaboration to Advance Quantum Mechanical Computations on Quantum Computers
Schrödinger and Qu & Co announced a business and scientific collaboration to advance the use of quantum mechanics on complex molecular systems using quantum computing hardware.
Extended collaboration leveraging Schrödinger’s computational platform includes new terms with increased and additional milestone payments to Schrödinger
Mr. Sender brings over 30 years of financial leadership experience, with a strong track record of success.
Schrödinger announced receipt of a milestone payment from Ono Pharmaceutical Co., Ltd. as part of a collaboration leveraging Schrödinger’s advanced computational platform to develop novel therapeutic candidates acting on the therapeutic target selected by Ono.
Milestone marks advancement of second drug discovery program under the collaboration
New hires to lead ADME/PK and Clinical Pharmacology for rapidly advancing internal pipeline programs
The financing is expected to be used to advance the company’s computational platform, as well as expand Schrödinger’s therapeutic pipeline.
New funding to support platform advancements and proprietary pipeline expansion
Schrödinger announced that the Company will be presenting on its advanced computational platform, which integrates physics-based molecular simulation and machine learning to accelerate drug discovery, at the upcoming conferences in May
The companies are currently advancing programs in oncology and autoimmune disease.
3/29/2019Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.
Schrödinger announced the appointment of Professor of Chemistry Brian Shoichet, Ph.D., a widely published thought leader in the field of computational drug discovery, to its scientific advisory board.
Schrödinger today announced the appointment of veteran biotech leader Rosana Kapeller, M.D., Ph.D., to its board of directors.
Schrödinger Closes $85 Million Financing to Advance Computational Platform and Expand Drug Discovery Pipeline
Investment in R&D will extend capabilities of computational platform and support growth of partnered and proprietary programs
Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments
Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program
Collaboration brings together Schrödinger’s in silico discovery capabilities with SPARC’s novel insights into CNS pathways to speed drug development
11/19/2018Companies bolstered their leadership with additions to boards of directors and c-suite offices.
Mr. Lebowitz, a longtime senior executive at Merck, brings to the company deep experience in finance and business development.